Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone

Exclusion Criteria

• •1. Methadone maintenance treatment or regular use of illicit methadone (\> 30 mg per week).
• •2. Maintenance on, or regular use of buprenorphine or other long-acting narcotic agonists.
• •3. Pregnancy, lactation, or failure in a sexually active woman to use adequate contraceptive methods.
• •4. Active medical illness which might make participation hazardous, such as untreated hypertension, hepatitis with SGOT or SGPT \> 3 times normal, unstable diabetes.
• •5. Active psychiatric disorder which might interfere with participation or make participation hazardous, including DSM-IV schizophrenia, bipolar disorder with mania or psychosis, and depressive disorder with suicide risk or 1 or more suicide attempts within the past year.
• •6. Physiologically dependent on alcohol or sedative-hypnotics with impending withdrawal. Other substance use diagnoses are not exclusionary. Multiple substance use is common in this population, and such an exclusion would rule out a large proportion of the population and limit the generalizability of the study.
• •7. History of allergic reaction to buprenorphine, naltrexone, naloxone, clonidine, or clonazepam.
• •8. Chronic organic mental disorder (e.g. AIDS dementia).
• •9. History of accidental drug overdose in the last 3 years as defined as an episode of opioid-induced unconsciousness or incapacitation, whether or not medical treatment was sought or received.
• •10. Currently receiving any other investigational drug, or has used any other investigational drug within 30 days of study entry.
• •11. Currently prescribed or regularly taking opiates for chronic pain or medical illness or those individuals anticipating surgical procedures which will necessitate opioid medications.